Induction therapy in renal transplantation
Induction Therapy in Renal Transplantation
Induction therapy is a process utilized to induce or create an immune tolerance in kidney transplant recipients. This is done to prevent the recipient’s immune system from rejecting the donor tissue. The aim of induction therapy in is to create an environment of immune tolerance, allowing the donor organ or tissue to be accepted by the recipient’s body. It leads to a decrease in acute rejection episodes, improved graft survival rates, and ultimately better outcomes for recipients.
The decision to use induction therapy for renal transplantation is based on a variety of factors, including the patient’s immunological profile, the degree of potential antibody-mediated rejection, and the risk of infection. The most commonly used agents in kidney transplant are polyclonal agents, such as basiliximab or alemtuzumab, and monoclonal antibodies, including anti-CD3 or anti-CD20.
Induction therapy has shown some benefits over no-induction in clinical trials. It has been associated with improved kidney allograft survival in the first year, fewer acute rejection episodes, better glomerular filtration rates, and improved patient survival. The primary adverse effect associated with the use of induction therapy is an increased risk of infection.
Benefits of Induction Therapy in Renal Transplantation
- Reduces the risk of acute rejection episodes
- Improves renal allograft survival
- Increases glomerular filtration rates
- Improves patient survival
- Reduces the risk of long-term donor-specific antibody formation
